Peri-implant reactivity and osteoinductive potential of immobilized rhBMP-2 on titanium carriers

Acta Biomater. 2010 Nov;6(11):4405-21. doi: 10.1016/j.actbio.2010.06.009. Epub 2010 Jun 15.

Abstract

Recombinant human BMP-2 (rhBMP-2) was immobilized non-covalently and covalently as a monolayer on plasma vapour deposited (PVD) porous commercially pure titanium surfaces in amounts of 5-8 μg cm(-2), providing a ca. 10-fold increase vs. previously reported values. Dissociation of the immobilized [125I]rhBMP-2 from the surface occurred in a two-phase exponential decay: a first rapid phase (ca. 15% of immobilized BMP-2) with a half-life of 1-2 days and a second slow sustained release phase (ca. 85% of immobilized BMP-2) with a half-life of 40-60 days. Dissociation rate constants of sustained release of k(-1)=1.3-1.9 x 10(-7)s(-1) were determined, allowing an estimation of the binding constants (K(A)) for the adsorbed rhBMP-2 monolayer, to be around 10(12) M(-1). The rhBMP-2-coated surfaces showed a high level of biological activity, as demonstrated by in vitro epifluorescence tests for alkaline phosphatase with MC3T3-E1 cells and in vivo experiments. In vivo osteoinductivity of rhBMP-2-coated implants was investigated in a gap-healing model in the trabecular bone of the distal femur condylus of sheep. Healing occurred without inflammation or capsule formation. The calculated concentration of released rhBMP-2 in the 1mm gap ranged from 20 to 98 nM--well above the half-maximal response concentration (K(0.5)) for inducing alkaline phosphatase in MC3T3-E1 cells. After 4, 9 and 12 weeks the bone density (BD) and bone-to-implant contact (BIC) of the explanted implants were assessed histomorphometrically. Implants with immobilized rhBMP-2 displayed a significant (2- to 4-fold) increase in BD and BIC values vs. negative controls after 4-9 weeks. Integration of implants by trabecular bone was achieved after 4 weeks, indicating a mean "gap-filling rate" of ∼250 μm week(-1). Integration of implants by cortical bone was observed after 9 weeks. Control implants without rhBMP-2 were not osseointegrated. This study demonstrates the feasibility of enhancing peri-implant osseointegration and gap bridging by immobilized rhBMP-2 on implant surfaces which may serve as a model for future clinical applications.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Alkaline Phosphatase / metabolism
  • Animals
  • Biological Assay
  • Bone Morphogenetic Protein 2
  • Bone Morphogenetic Proteins / pharmacology*
  • Femur / drug effects
  • Femur / pathology
  • Fluorescence
  • Half-Life
  • Humans
  • Immobilized Proteins / pharmacology*
  • Implants, Experimental*
  • Kinetics
  • Mice
  • Nanostructures / ultrastructure
  • Osseointegration / drug effects*
  • Osteoblasts / cytology
  • Osteoblasts / drug effects
  • Osteoblasts / enzymology
  • Recombinant Proteins / pharmacology*
  • Sheep
  • Surface Properties / drug effects
  • Tissue Scaffolds / chemistry*
  • Titanium / pharmacology*
  • Transforming Growth Factor beta / pharmacology*
  • Wettability / drug effects
  • Wound Healing / drug effects

Substances

  • Bone Morphogenetic Protein 2
  • Bone Morphogenetic Proteins
  • Immobilized Proteins
  • Recombinant Proteins
  • Transforming Growth Factor beta
  • recombinant human bone morphogenetic protein-2
  • Titanium
  • Alkaline Phosphatase